News

Genevant and Arbutus Launch Patent Enforcement Against Moderna

Genevant and Arbutus Launch Patent Enforcement Against Moderna

Genevant Sciences and Arbutus Biopharma Take a Stand

Genevant Sciences, renowned for its leading-edge nucleic acid delivery technology, and Arbutus Biopharma, an innovative player focusing on infectious diseases, have united to assert their patents about lipid nanoparticle (LNP) technology. This legal move comes as both companies embark on international patent infringement enforcement actions against Moderna, Inc. and affiliated entities. Together, they are challenging practices that they allege infringe their proprietary LNP technology across 30 countries.

The Initiation of International Lawsuits

The companies have filed five international lawsuits aimed at defending their intellectual property rights. They are pursuing financial relief as well as injunctions against products developed by Moderna, specifically targeting Spikevax and potentially other products which the company claims utilize the same technological foundation.

Details of the Legal Filings

The legal actions are far-reaching, with notable cases in key jurisdictions. In Canada, the Federal Court is considering a case involving a permanent injunction under Canadian Patent No. 2,721,333. Similarly, lawsuits have been initiated in Japan and Switzerland, seeking substantial monetary relief and assurances against further infractions.

Multi-Country Enforcement Actions

The lawsuits are not limited to single regions but extend to the Unified Patent Court (UPC). This court is reviewing claims involving multiple European nations, indicating a collaborative effort to protect innovative technologies on a global scale. Genevant and Arbutus aim to obtain recovery of unfair profits from Moderna across several significant markets in Europe.

Technological Background and Importance

The backbone of this legal action revolves around the crucial LNP delivery technology, which has been critical in the mRNA medicine revolution. Genevant and Arbutus have devoted years to perfecting this technology, which is designed to safely transport mRNA to human cells. The patented technology ensures stability and effectiveness by shielding mRNA molecules with meticulously selected lipid layers.

Commercial Applications of LNP Technology

Over the years, the LNP technology developed by Genevant has not only bolstered vaccines but also has links to potential applications in therapeutic protein production and gene editing. This versatility showcases the immense value of what is at stake—not just for the companies involved, but for public health innovations globally.

The Future Outlook

As these actions unfold in courts across the globe, the upcoming jury trial in Delaware is a pivotal moment in the ongoing litigation saga against Moderna. Scheduled for September 2025, the outcome could reshape the landscape of mRNA delivery technology and its patent implications.

About Genevant Sciences

Genevant Sciences stands as a significant force in nucleic acid delivery, equipped with advanced platforms and a substantial patent portfolio. With over two decades of specialized experience in LNP technologies, Genevant aims to drive innovations that will lead to groundbreaking advancements in RNA-based therapies.

About Arbutus Biopharma

Arbutus Biopharma Corporation continues to make strides in the realm of infectious diseases, particularly with treatments targeting chronic hepatitis B. Through its stake in Genevant, it seeks to optimize commercial opportunities linked to LNP technologies, making significant contributions to the pharmaceutical landscape.

Frequently Asked Questions

What companies are involved in the patent enforcement actions?

Genevant Sciences and Arbutus Biopharma have initiated the actions against Moderna, Inc.

How many countries are affected by the lawsuits?

The enforcement actions target alleged infringing activities across 30 countries.

What technology is at the center of these lawsuits?

The lawsuits focus on lipid nanoparticle (LNP) technology used in mRNA delivery systems.

What are Genevant's and Arbutus' goals with these lawsuits?

They aim to seek monetary relief and injunctions to protect their patents on LNP technology.

When is the jury trial scheduled?

A jury trial is set for September 2025 in the U.S., which could have significant implications for the litigation.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Apotex Enters U.S. Market with Axitinib Tablets Launch

Updated Category News Views 114

Apotex's Bold Move: Axitinib Tablets Hit the U.S. Market Apotex is shaking things up in the pharma world by launching the first generic version of Axitinib Tablets in the U.S., aimed at treating advanced renal cell carcinoma (RCC) when previous treatments have fallen flat. This isn't just another dance with the red tape—it's a major step for Apotex, flexing their muscle...

Continue Reading
Rock & Roll Hall of Fame's 2026 Induction Triumph

Updated Category News Views 180

A Night of Unstoppable Talent The Rock & Roll Hall of Fame's 2026 Induction Ceremony and boy, what a spectacle it was. Held on a lively Saturday night, November 14, in Los Angeles, it wasn't just an event; it was an electrifying testament to music's profound impact. With the grand ceremony kicking off at the historic city of stars, this year's induction turned the dial to...

Continue Reading
Ross Pools Joins Forces with Florida Panthers in 2026

Updated Category News Views 104

An Unlikely Team-Up: Pools and Hockey Well, here's one for the books: a South Florida pool company hitching its wagon to an NHL team. Ross Pools, the folks who’ve been carving out backyard oases in the sizzling Florida sun for over two decades, are now officially aligned with the Florida Panthers. Yeah, the same Panthers that snatched the Stanley Cup not once but twice...

Continue Reading
Biotech Hit or Miss: Trials and Tribulations

Updated Category News Views 96

Biotech's Roller Coaster: Triumphs and Setbacks Ah, the biotech sector—it's a bit like jumping on a bull, ain't it? You barely hang on when the beast bucks. Monday's market action was downright wild. The S&P 500 didn't have a party, tumbling 1.92%, and the Nasdaq wasn't any friendlier, plummeting 2.49%. Yet, inside this storm, we see some biotech names either catching...

Continue Reading
Hermes AI: A New Era in Market Analysis?

Updated Category News Views 111

Revolution or Just Another App? In a world where stock market insights are as cryptic as hieroglyphs to the average Joe, here comes the Hermes AI Analyzer, breaking onto the scene and promising to translate Wall Street's complex lingo into plain, simple language. It's the brainchild of Turkish engineer Umut Tugrul, who has spent decades in the trenches of software...

Continue Reading
Loyalty Programs Cut $1500 Annually for Consumers

Updated Category News Views 132

Loyalty Programs: An Essential Tool for Households In a world where every dollar counts, retail loyalty programs have become more than just a marketing strategy—they're lifelines for American households scraping through each month. According to fresh research by the Retail Industry Leaders Association (RILA) and conducted by market research leader Circana, these...

Continue Reading
Luxury Villa Cashback Offers Entice Travelers in November

Updated Category News Views 134

A November Bonanza for Villa Bookings Who doesn't love having a few extra bucks in their pocket, especially when they come with the allure of luxury travel? Villas of Distinction is rolling out what they call a 'November Cashback Offer,' and for those with the wallet—and wanderlust—to match, it could be a tempting proposition. Hanging the bait of up to $2,000 cashback...

Continue Reading
Teamsters Ratify Contract, Averting Waste Strike

Updated Category News Views 117

Big Win for Teamsters Local 350 You ever seen a strike averted by sheer willpower and unity? That’s what's happened here with the workers at South San Francisco Scavenger Company. These folks—drivers, mechanics, sorters, and utility workers—all banded together under the Teamsters Local 350 and showed management what's what by securing a contract they deserve. We're...

Continue Reading
Webull Faces FINRA Fine and Legal Battle Ahead

Updated Category News Views 187

Webull's Compliance Headache Webull’s been knocked around again. This time, the Financial Industry Regulatory Authority (FINRA) slapped it with a hefty $4.2 million fine. Talk about a hit to the wallet! It all boils down to them failing to roll out some basic anti-money laundering (AML) and other crucial compliance programs. This is no small oversight, and it's got...

Continue Reading
Ainstein Expands Kansas Operations Amid Sensor Demand Surge

Updated Category News Views 133

Ainstein's Expansion Conquers New Heights in Radar Tech Ainstein just cranked open a whole new chapter right in the heart of Kansas. And believe me, it's not your average ribbon-cutting story. This shiny new facility in Lenexa is locked and loaded to roll out 44,000 radar sensors a year. It's part of a no-nonsense plan to keep up with soaring demand for their tech across...

Continue Reading

Top 5 Most Recently Viewed Articles

Unlocking the Future of Health with ELMCRx and ETS Partnership

Updated Category News Views 154

ELMCRx Solutions and ETS Partnership ELMCRx Solutions is forging new paths within the healthcare landscape through its strategic alliance with Emerging Therapy Solutions (ETS). This collaboration is tailored to address the innovative and costly challenges posed by cell and gene therapies (CGT). ELMCRx stands out as a pharmacy benefit manager (PBM) dedicated to providing...

Continue Reading
International Symposium on Microbes and Cancer Research

Updated Category News Views 203

International Symposium on Microbes and Cancer Research Set for March 2-3, the upcoming conference promises to bring together globally recognized experts from various fields related to cancer science. The event, hosted by Tampa General Hospital (TGH) Cancer Institute and the USF Health Morsani College of Medicine, will highlight critical intersections between microbes,...

Continue Reading
Freddie Mac Welcomes Matthew Abrusci as New General Counsel

Updated Category News Views 314

Freddie Mac Names Matthew Abrusci as General Counsel MCLEAN, Va. — Freddie Mac (OTCQB: FMCC) proudly announces the appointment of Matthew D. Abrusci as its new Executive Vice President, General Counsel, and Corporate Secretary. With his extensive experience in financial services, Abrusci is set to make significant contributions to the organization. Matthew Abrusci's...

Continue Reading
Energizer Holdings Declares Increased Dividend for Shareholders

Updated Category News Views 188

Energizer Holdings Announces Dividend for Shareholders Energizer Holdings, Inc. (NYSE: ENR) recently declared a quarterly dividend, highlighting the company’s ongoing dedication to its investors. The Board of Directors determined that each share of common stock will receive a dividend of $0.30, reflecting the organization's solid performance and commitment to returning...

Continue Reading
Tevogen Bio: Pioneering Cost-Effective Innovations in Biopharma

Updated Category News Views 199

Tevogen Bio's Innovative Approach to Healthcare As the biopharma sector navigates an increasingly competitive landscape, Tevogen Bio Holdings Inc. (NASDAQ: TVGN) stands out for its commitment to delivering groundbreaking medical solutions while maintaining affordability. This dedication is crucial as international competitors, particularly from China, develop drugs more...

Continue Reading